Evidence map›Paper›PMID 24245566›Full record

Trial reportThe New England journal of medicine2014

Stenting and medical therapy for atherosclerotic renal-artery stenosis.

Christopher J Cooper, Timothy P Murphy, Donald E Cutlip, Kenneth Jamerson, William Henrich, Diane M Reid, David J Cohen, Alan H Matsumoto, Michael Steffes, Michael R Jaff and 9 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00081731 (Cardiovascular Outcomes in Renal Atherosclerotic Lesions), which is not on this map. Cited by 359 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
359citing papers in PubMed, 9 pooled it
81.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081731 phase3completednot on this map

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

TypeinterventionalSponsorBaim Institute for Clinical ResearchRan2004 to 2013Enrolled947ConditionsAtherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery ObstructionArmsAtacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
3 · Its place in the literature

Who cites it

359 citing papers in PubMed, 9 syntheses or guidelines pooled it, 996 citations in OpenAlex.

  1. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2020
    Guideline
  7. Pooled it
  8. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Guideline
  9. Guideline
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

299 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 2 countries.

Christopher J CooperFrom the University of Toledo, Toledo, OH (C.J.C.); Rhode Island Hospital (T.P.M., L.D.D.) and Alpert Medical School of Brown University (T.P.M., L.D.D.) - both in Providence; Harvard Clinical Research Institute (D.E.C., J.M.M., R.B.D.), Beth Israel Deaconess Medical Center (D.E.C.), Massachusetts General Hospital (M.R.J.), Brigham and Women's Hospital (E.F.L.), and Boston University School of Public Health (R.B.D.) - all in Boston; University of Michigan, Ann Arbor (K.J.); University of Texas Health Science Center, San Antonio (W.H.); National Heart, Lung and Blood Institute, Bethesda, MD (D.M.R.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); University of Virginia, Charlottesville (A.H.M.); University of Minnesota, Minneapolis (M.S.); Weill Cornell Medical Center, New York (M.R.P.); Providence Sacred Heart Medical Center and University of Washington School of Medicine, Spokane (K.R.T.); Marshall University, Huntington, WV (J.I.S.); and Holy Name Medical Center, Teaneck NJ (J.H.R.).
Timothy P Murphy
Donald E Cutlip
Kenneth Jamerson
William Henrich
Diane M Reid
David J Cohen
Alan H Matsumoto
Michael Steffes
Michael R Jaff
Martin R Prince
Eldrin F Lewis
Katherine R Tuttle
Joseph I Shapiro
John H Rundback
Joseph M Massaro
Ralph B D'Agostino
Lance D Dworkin
CORAL Investigators
Baim Institute for Clinical Research · USThe University of Texas Health Science Center at San Antonio · USBrigham and Women's Hospital · USBrown University · USCornell University · USHoly Name Medical Center · USMarshall University · USMassachusetts General Hospital · USNational Heart Lung and Blood Institute · USProvidence Sacred Heart Medical Center · USRhode Island Hospital · USSaint Luke's Hospital · USUniversity of Michigan–Ann Arbor · USUniversity of Minnesota System · USUniversity of Virginia · US

Funding

CORAL: Clinical Coordinating CenterU01HL071556 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COOPER, CHRISTOPHER J · 2004 to 2013
$19.3M
CORAL: Data Coordinating CenterU01HL072737 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CUTLIP, DONALD · 2004 to 2013
$9.4M
CORAL: Economics and QOL Core LaboratoryU01HL072736 · NHLBI · SAINT LUKE'S HOSPITAL · PI COHEN, DAVID J · 2004 to 2013
$2.6M
CORAL Angiographic Core LaboratoryU01HL072735 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI MATSUMOTO, ALAN H. · 2004 to 2010
$1.4M
Coral: Central GFR and Biochemistry LaboratoryU01HL072734 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI STEFFES, MICHAEL W. · 2004 to 2012
$1.3M
NHLBI NIH HHS U01 HL071556NHLBI NIH HHS U01HL071556NHLBI NIH HHS U01 HL072734NHLBI NIH HHS U01HL072734NHLBI NIH HHS U01 HL072735NHLBI NIH HHS U01HL072735NHLBI NIH HHS U01 HL072736NHLBI NIH HHS U01HL072736NHLBI NIH HHS U01 HL072737NHLBI NIH HHS U01HL072737
6 · The paper itself

Abstract

backgroundAtherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and cardiovascular events is uncertain.

methodsWe randomly assigned 947 participants who had atherosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medical therapy plus renal-artery stenting or medical therapy alone. Participants were followed for the occurrence of adverse cardiovascular and renal events (a composite end point of death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement therapy).

resultsOver a median follow-up period of 43 months (interquartile range, 31 to 55), the rate of the primary composite end point did not differ significantly between participants who underwent stenting in addition to receiving medical therapy and those who received medical therapy alone (35.1% and 35.8%, respectively; hazard ratio with stenting, 0.94; 95% confidence interval [CI], 0.76 to 1.17; P=0.58). There were also no significant differences between the treatment groups in the rates of the individual components of the primary end point or in all-cause mortality. During follow-up, there was a consistent modest difference in systolic blood pressure favoring the stent group (-2.3 mm Hg; 95% CI, -4.4 to -0.2; P=0.03).

conclusionsRenal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease. (Funded by the National Heart, Lung and Blood Institute and others; ClinicalTrials.gov number, NCT00081731.).

Indexed as

StentsAgedAmlodipineAngioplasty, BalloonAngiotensin II Type 1 Receptor BlockersAnticholesteremic AgentsAntihypertensive AgentsCardiovascular DiseasesCombined Modality TherapyDrug CombinationsFemaleFollow-Up StudiesHeptanoic AcidsHumansHypertensionKaplan-Meier EstimateAmlodipineamlodipine, atorvastatin drug combinationAngiotensin II Type 1 Receptor BlockersAnticholesteremic AgentsAntihypertensive AgentsDrug CombinationsHeptanoic AcidsPyrroles

Identifiers

PMID24245566
PMCPMC4815927
OpenAlexW2148367988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.